Lanter James C, Fiordeliso James J, Jiang Weiqin, Allan George F, Lai Muh-Tsann, Linton Olivia, Hahn Do Won, Lundeen Scott G, Sui Zhihua
Johnson & Johnson Pharmaceutical Research and Development L.L.C., 666 Stockton Drive, Exton, PA 19341, USA.
Bioorg Med Chem Lett. 2007 Jan 1;17(1):123-6. doi: 10.1016/j.bmcl.2006.09.086. Epub 2006 Sep 30.
A series of novel 2-(1H-indol-2-yl)-propan-2-ols have been designed, synthesized, and screened for their ability to inhibit testosterone-induced prostate weight increases in immature rats. Through the use of this paradigm, we were able to identify compounds that exhibited in vivo potency equal to that of the marketed antiandrogen Casodex when orally administered.
设计、合成了一系列新型的2-(1H-吲哚-2-基)-丙-2-醇,并对其抑制未成熟大鼠睾丸素诱导的前列腺重量增加的能力进行了筛选。通过使用这种模式,我们能够鉴定出经口服给药后,体内效力与市售抗雄激素药物康士得相当的化合物。